{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:21Z","timestamp":1791402321239,"version":"4.3.3"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with haematological malignancies (HM) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality. We reviewed data published until September 2021 to update the 2017 antifungal prophylaxis recommendations of the German Society of Haematology and Medical Oncology (DGHO). The strong recommendation to administer antifungal prophylaxis in patients with HM with long-lasting neutropenia, i.e. &amp;lt;500 cells\/\u03bcL for &amp;gt;7 days remains unchanged. Posaconazole remains the drug of choice for mould-active prophylaxis in these patients. Novel treatment options in HM, such as CAR-T-cell treatment or novel targeted therapies for acute myeloid leukaemia (AML) were considered, however, data are insufficient to give general recommendations for routine antifungal prophylaxis in these patients. Major changes regarding specific recommendations compared to the 2017 edition are the now moderate instead of mild support for the recommendations of isavuconazole and voriconazole. Furthermore, published evidence on micafungin allows recommending it at moderate strength for its use in HM. For the first time we included recommendations for non-pharmaceutical measures regarding IFD, comprising the use of high-efficiency particulate air (HEPA) filters, smoking, measures during construction work and neutropenic diets.<\/jats:p><jats:p>We reviewed the impact of antifungal prophylaxis with triazoles on drug\u2013drug interactions with novel targeted therapies that are metabolized via cytochrome p450 where triazoles inhibit CYP3A4\/5. The working group recommends reducing the dose of venetoclax when used concomitantly with strong CYP3A4 inhibiting antifungals. Furthermore, we reviewed data on the prophylactic use of novel antifungal agents. Currently there is no evidence to support their use in a prophylactic setting in clinical practice.<\/jats:p>","DOI":"10.1093\/jac\/dkad143","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T19:33:58Z","timestamp":1686684838000},"page":"1813-1826","source":"Crossref","is-referenced-by-count":98,"title":["Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-2469","authenticated-orcid":false,"given":"Jannik","family":"Stemler","sequence":"first","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) , Cologne , Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne , Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3928-2503","authenticated-orcid":false,"given":"Sibylle C","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) , Cologne , Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne , Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-0967","authenticated-orcid":false,"given":"Yascha","family":"Khodamoradi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2457-6437","authenticated-orcid":false,"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) , Cologne , Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne , Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-5139","authenticated-orcid":false,"given":"Annika Y","family":"Classen","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) , Cologne , Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja E","family":"Zapke","sequence":"additional","affiliation":[{"name":"Department Hematology, Oncology, Infectious disease and Palliatve Care, Helios University Hospital Wuppertal , Wuppertal , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-2824","authenticated-orcid":false,"given":"Martin","family":"Hoenigl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria and BioTechMed , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-3648","authenticated-orcid":false,"given":"Robert","family":"Krause","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria and BioTechMed , Graz , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-6945","authenticated-orcid":false,"given":"Martin","family":"Schmidt-Hieber","sequence":"additional","affiliation":[{"name":"2nd Medical Clinic (Hematology, Oncology, Pneumology, Nephrology) , Carl-Thiem Clinic Cottbus, Cottbus , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-9202","authenticated-orcid":false,"given":"Werner J","family":"Heinz","sequence":"additional","affiliation":[{"name":"Medical Clinic II, Caritas Hospital , Bad Mergentheim , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology , Klinikum Vest, Knappschaftskrankenhaus, Recklinghausen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-7495","authenticated-orcid":false,"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) , Cologne , Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-3450","authenticated-orcid":false,"given":"Blasius","family":"Liss","sequence":"additional","affiliation":[{"name":"Department Hematology, Oncology, Infectious disease and Palliatve Care, Helios University Hospital Wuppertal , Wuppertal , Germany"},{"name":"School of Medicine, Faculty of Health, Witten\/Herdecke University , Witten , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5884","authenticated-orcid":false,"given":"Michael","family":"Koldehoff","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , Essen , Germany"},{"name":"Department of Hygiene and Environmental Medicine, University Hospital Essen, University of Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Buhl","sequence":"additional","affiliation":[{"name":"Medical Clinic III, Hospital Leverkusen , Leverkusen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin , Berlin , Germany"},{"name":"Humboldt-Universit\u00e4t zu Berlin, Department of Hematology, Oncology and Tumorimmunology , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-2466","authenticated-orcid":false,"given":"Georg","family":"Maschmeyer","sequence":"additional","affiliation":[{"name":"Formerly Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann , Potsdam , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-5098","authenticated-orcid":false,"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, Medical Centre, Otto-von-Guericke University Magdeburg , Magdeburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-7785","authenticated-orcid":false,"given":"Cornelia","family":"Lass-Fl\u00f6rl","sequence":"additional","affiliation":[{"name":"Institute of Hygiene and Medical Microbiology, ECMM Excellence Centre, Medical University of Innsbruck , Innsbruck , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-9729","authenticated-orcid":false,"given":"Meinolf","family":"Karthaus","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care, Klinikum Neuperlach , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ruhnke","sequence":"additional","affiliation":[{"name":"Helios Klinikum Aue, Klinik f\u00fcr H\u00e4matologie\/Onkologie & Palliativmedizin , Aue , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM) , Cologne , Germany"},{"name":"German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne , Cologne , Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne, NRW , Germany"},{"name":"University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS K\u00f6ln) , Cologne , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-8060","authenticated-orcid":false,"given":"Daniel","family":"Teschner","sequence":"additional","affiliation":[{"name":"Department of Hematology, and Medical Oncology, University Medical Center of the Johannes Gutenberg University , Mainz , Germany"},{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"2023080202252194900_dkad143-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2016.09.002","article-title":"Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations","volume":"31","author":"Pagano","year":"2017","journal-title":"Blood Rev"},{"key":"2023080202252194900_dkad143-B2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","article-title":"Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study","volume":"49","author":"Koehler","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023080202252194900_dkad143-B3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/myc.13130","article-title":"Candidaemia in haematological malignancy patients from a SEIFEM study: epidemiological patterns according to antifungal prophylaxis","volume":"63","author":"Posteraro","year":"2020","journal-title":"Mycoses"},{"key":"2023080202252194900_dkad143-B4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jof7080588","article-title":"Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach","volume":"7","author":"Bergamasco","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2023080202252194900_dkad143-B5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"key":"2023080202252194900_dkad143-B6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QCO.0000000000000737","article-title":"Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients","volume":"34","author":"Coussement","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"2023080202252194900_dkad143-B7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/myc.13148","article-title":"Breakthrough invasive fungal infections: who is at risk?","volume":"63","author":"Jenks","year":"2020","journal-title":"Mycoses"},{"key":"2023080202252194900_dkad143-B8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2023080202252194900_dkad143-B9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202252194900_dkad143-B10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/jof7020156","article-title":"Invasive fungal infections after anti-CD19 chimeric antigen receptor-modified T-cell therapy: state of the evidence and future directions","volume":"7","author":"Garner","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2023080202252194900_dkad143-B11","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1016\/S2352-3026(21)00270-2","article-title":"Harnessing the benefits of available targeted therapies in acute myeloid leukaemia","volume":"8","author":"Kantarjian","year":"2021","journal-title":"Lancet Haematol"},{"key":"2023080202252194900_dkad143-B12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","article-title":"Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO)","volume":"100","author":"Christopeit","year":"2021","journal-title":"Ann Hematol"},{"key":"2023080202252194900_dkad143-B13","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann Hematol"},{"key":"2023080202252194900_dkad143-B14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","article-title":"Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the infectious diseases working party of the German Society of Hematology and Medical Oncology (AGIHO\/DGHO)","volume":"100","author":"Classen","year":"2021","journal-title":"Ann Hematol"},{"issue":"Suppl 3","key":"2023080202252194900_dkad143-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12569","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2023080202252194900_dkad143-B16","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-014-2108-y","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the infectious diseases working party of the German Society for Haematology and Oncology","volume":"93","author":"Tacke","year":"2014","journal-title":"Ann Hematol"},{"key":"2023080202252194900_dkad143-B17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.11665","article-title":"Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the infectious diseases working party of the German Society for Haematology and Oncology","volume":"94","author":"Cornely","year":"2009","journal-title":"Haematologica"},{"key":"2023080202252194900_dkad143-B18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/jac\/dkx133","article-title":"Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. f luconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2023080202252194900_dkad143-B20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2005.05608.x","article-title":"Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial","volume":"130","author":"Reich","year":"2005","journal-title":"Br J Haematol"},{"key":"2023080202252194900_dkad143-B21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1128\/AAC.01985-15","article-title":"Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis","volume":"60","author":"Zhao","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/jac\/dkw079","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B24","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B25","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1093\/jac\/dkx382","article-title":"Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00893-18","article-title":"Clinical outcomes of oral suspension versus delayed-release tablet formulations of posaconazole for prophylaxis of invasive fungal infections","author":"Furuno","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/myc.12728","article-title":"Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: a real-world comparison","volume":"61","author":"Tormo","year":"2018","journal-title":"Mycoses"},{"key":"2023080202252194900_dkad143-B28","article-title":"Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: a single-center, observational, case-control study in South Korea","volume":"100","author":"Yang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2023080202252194900_dkad143-B29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/jama.2019.15702","article-title":"Effect of caspofungin vs fluconazole prophylaxis on invasive fungal disease among children and young adults with acute myeloid leukemia: a randomized clinical trial","volume":"322","author":"Fisher","year":"2019","journal-title":"JAMA"},{"key":"2023080202252194900_dkad143-B30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/mmy\/myab025","article-title":"Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients","volume":"59","author":"Bogler","year":"2021","journal-title":"Med Mycol"},{"key":"2023080202252194900_dkad143-B31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bbmt.2020.02.009","article-title":"A single-center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation","volume":"26","author":"Stern","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023080202252194900_dkad143-B32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/cid\/ciaa652","article-title":"Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients","volume":"73","author":"Samanta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023080202252194900_dkad143-B33","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/cid\/ciaa358","article-title":"Isavuconazole as primary antifungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase 2 study","volume":"72","author":"Bose","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023080202252194900_dkad143-B34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023080202252194900_dkad143-B35","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B36","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 1","key":"2023080202252194900_dkad143-B37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023080202252194900_dkad143-B38","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"2023080202252194900_dkad143-B39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/1078155219876683","article-title":"Voriconazole prophylaxis in leukemic patients: a retrospective single-center study","volume":"26","author":"Bui","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2023080202252194900_dkad143-B40","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ijantimicag.2017.03.021","article-title":"Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies","volume":"50","author":"Hachem","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023080202252194900_dkad143-B41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jiac.2017.02.011","article-title":"Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China","volume":"23","author":"Xu","year":"2017","journal-title":"J Infect Chemother"},{"key":"2023080202252194900_dkad143-B42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cpt.1641","article-title":"Prospective CYP2C19-guided voriconazole prophylaxis in patients with neutropenic acute myeloid leukemia reduces the incidence of subtherapeutic antifungal plasma concentrations","volume":"107","author":"Hicks","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2023080202252194900_dkad143-B43","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s10147-019-01506-x","article-title":"Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study","volume":"24","author":"Tsutsumi","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2023080202252194900_dkad143-B44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/1078155218806975","article-title":"Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"25","author":"Phillips","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2023080202252194900_dkad143-B45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.mycmed.2017.11.003","article-title":"Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: a retrospective study","volume":"28","author":"Tang","year":"2018","journal-title":"J Mycol Med"},{"key":"2023080202252194900_dkad143-B46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105886","article-title":"Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: a retrospective study","volume":"55","author":"Copley","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2023080202252194900_dkad143-B47","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1093\/jac\/dkx295","article-title":"Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation","volume":"72","author":"Lindsay","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B48","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dkz303","article-title":"Clinical experience with new formulation SUBA\u00ae-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies","volume":"74","author":"Nield","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B49","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13587","article-title":"A novel highly bio-available itraconazole formulation (SUBA\u00ae-itraconazole) for anti-fungal prophylaxis in lung transplant recipients","volume":"23","author":"Whitmore","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"2023080202252194900_dkad143-B50","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/odi.13588","article-title":"Antifungal agents in preventing oral candidiasis in clinical oncology: a network meta-analysis","volume":"27","author":"Shen Loo","year":"2021","journal-title":"Oral Dis"},{"key":"2023080202252194900_dkad143-B51","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/myc.13177","article-title":"Attributable mortality of candidemia after introduction of echinocandins","volume":"63","author":"Cornely","year":"2020","journal-title":"Mycoses"},{"key":"2023080202252194900_dkad143-B52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jpids\/piaa119","article-title":"A randomized trial of caspofungin vs triazoles prophylaxis for invasive fungal disease in pediatric allogeneic hematopoietic cell transplant","volume":"10","author":"Dvorak","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2023080202252194900_dkad143-B53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.37201\/req\/094.2019","article-title":"Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)","volume":"33","author":"L\u00f3pez-S\u00e1nchez","year":"2020","journal-title":"Rev Esp Quimioter"},{"key":"2023080202252194900_dkad143-B54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/myc.13232","article-title":"Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: a six-year cohort analysis","volume":"64","author":"Wingen-Heimann","year":"2021","journal-title":"Mycoses"},{"key":"2023080202252194900_dkad143-B55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.13372","article-title":"Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: a retrospective analysis","volume":"104","author":"Rothe","year":"2020","journal-title":"Eur J Haematol"},{"key":"2023080202252194900_dkad143-B56","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jinf.2018.03.015","article-title":"Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study","volume":"77","author":"Epstein","year":"2018","journal-title":"J Infect"},{"key":"2023080202252194900_dkad143-B57","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s11605-019-04241-w","article-title":"A multicenter, randomized, open-label study to compare micafungin with fluconazole in the prophylaxis of invasive fungal infections in living-donor liver transplant recipients","volume":"24","author":"Kang","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"2023080202252194900_dkad143-B58","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jinf.2016.06.011","article-title":"Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients","volume":"73","author":"Park","year":"2016","journal-title":"J Infect"},{"key":"2023080202252194900_dkad143-B59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.medmal.2016.03.008","article-title":"Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia","volume":"46","author":"Venton","year":"2016","journal-title":"Med Mal Infect"},{"key":"2023080202252194900_dkad143-B60","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial","volume":"17","author":"Penack","year":"2006","journal-title":"Ann Oncol"},{"key":"2023080202252194900_dkad143-B61","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab113","article-title":"When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients","volume":"8","author":"Batchelor","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023080202252194900_dkad143-B62","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1078155214560920","article-title":"Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease","volume":"22","author":"Luu Tran","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"2023080202252194900_dkad143-B63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/jof6040385","article-title":"Safety and efficacy of intermittent high-dose liposomal amphotericin B antifungal prophylaxis in haemato-oncology: an eight-year single-centre experience and review of the literature","volume":"6","author":"Youngs","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2023080202252194900_dkad143-B64","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023080202252194900_dkad143-B65","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2015.02.023","article-title":"Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: efficacy and cost effectiveness in real-life","volume":"46","author":"Chong","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2023080202252194900_dkad143-B66","article-title":"Nystatin prophylaxis and treatment in severely immunodepressed patients","volume":"2014","author":"G\u00f8tzsche","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023080202252194900_dkad143-B67","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00277-015-2333-z","article-title":"Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients\u2013an evidence-based approach","volume":"94","author":"Karthaus","year":"2015","journal-title":"Ann Hematol"},{"key":"2023080202252194900_dkad143-B68","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023080202252194900_dkad143-B69","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1093\/jac\/dkac196","article-title":"Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation","volume":"77","author":"Kriegl","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B70","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1128\/AAC.00389-16","article-title":"Posaconazole plasma concentrations on days three to five predict steady-state levels","volume":"60","author":"Prattes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B71","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023080202252194900_dkad143-B72","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin Ther"},{"key":"2023080202252194900_dkad143-B73","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","article-title":"How we incorporate venetoclax in treatment regimens for acute myeloid leukemia","volume":"28","author":"Maiti","year":"2022","journal-title":"Cancer J"},{"key":"2023080202252194900_dkad143-B74","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch","year":"2021","journal-title":"Cancer"},{"key":"2023080202252194900_dkad143-B75","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2019-131988","article-title":"Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia","volume":"134","author":"Rausch","year":"2019","journal-title":"Blood"},{"key":"2023080202252194900_dkad143-B76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","article-title":"Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)","volume":"90","author":"Sechaud","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023080202252194900_dkad143-B77","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106610","article-title":"Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib","volume":"108","author":"Aleissa","year":"2021","journal-title":"Leuk Res"},{"key":"2023080202252194900_dkad143-B78","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1182\/blood-2018-99-115993","article-title":"Single centre experience in treating elderly patients with acute myeloid leukaemia or high risk myelodysplastic syndrome with a combination of low dose cytarabine, venetoclax and fluconazole (VeLDAC-F)","volume":"132","author":"Child","year":"2018","journal-title":"Blood"},{"key":"2023080202252194900_dkad143-B79","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023080202252194900_dkad143-B80","author":"Food and Drug Administration"},{"key":"2023080202252194900_dkad143-B81","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"2023080202252194900_dkad143-B82","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2023080202252194900_dkad143-B83","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023080202252194900_dkad143-B84","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/bmjspcare-2018-001742","article-title":"Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis","volume":"9","author":"Sonbol","year":"2019","journal-title":"BMJ Support Palliat Care"},{"key":"2023080202252194900_dkad143-B85","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1200\/JCO.2008.16.4681","article-title":"Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia","volume":"26","author":"Gardner","year":"2008","journal-title":"J Clin Oncol"},{"key":"2023080202252194900_dkad143-B86","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejca.2021.06.054","article-title":"Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer","volume":"155","author":"Jakob","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023080202252194900_dkad143-B87","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/annonc\/mdp034","article-title":"A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients","volume":"20","author":"Maschmeyer","year":"2009","journal-title":"Ann Oncol"},{"key":"2023080202252194900_dkad143-B88","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/ejh.12991","article-title":"Cost-effectiveness analysis of interventions for prevention of invasive aspergillosis among leukemia patients during hospital construction activities","volume":"100","author":"Combariza","year":"2018","journal-title":"Eur J Haematol"},{"key":"2023080202252194900_dkad143-B89","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/sj.bmt.1701238","article-title":"Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia","volume":"21","author":"Passweg","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2023080202252194900_dkad143-B90","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4274\/tjh.2014.0010","article-title":"A quasi-experimental study analyzing the effectiveness of portable high-efficiency particulate absorption filters in preventing infections in hematology patients during construction","volume":"33","author":"\u00d6zen","year":"2016","journal-title":"Turk J Haematol"},{"key":"2023080202252194900_dkad143-B91","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12879-018-3665-9","article-title":"Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study","volume":"19","author":"Iwasaki","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2023080202252194900_dkad143-B92","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/annonc\/mdw275","article-title":"A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients","volume":"27","author":"Biehl","year":"2016","journal-title":"Ann Oncol"},{"key":"2023080202252194900_dkad143-B93","article-title":"Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2023080202252194900_dkad143-B94","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.20.01739","article-title":"Open-label phase II prospective, randomized, controlled study of romyelocel-L myeloid progenitor cells to reduce infection during induction chemotherapy for acute myeloid leukemia","volume":"39","author":"Desai","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023080202252194900_dkad143-B95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2017.02.003","article-title":"Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies","volume":"57","author":"Kang","year":"2017","journal-title":"Leuk Res"},{"key":"2023080202252194900_dkad143-B96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197851","article-title":"Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study","volume":"13","author":"Lien","year":"2018","journal-title":"PLoS ONE"},{"key":"2023080202252194900_dkad143-B97","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jmii.2018.09.006","article-title":"Invasive mold infections in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"52","author":"Chien","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"2023080202252194900_dkad143-B98","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3324\/haematol.2014.113399","article-title":"Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)","volume":"100","author":"Caira","year":"2015","journal-title":"Haematologica"},{"key":"2023080202252194900_dkad143-B99","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00311-20","article-title":"Aspergillus terreus species complex","volume":"34","author":"Lass-Fl\u00f6rl","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"2023080202252194900_dkad143-B100"},{"key":"2023080202252194900_dkad143-B101","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jhin.2017.04.022","article-title":"Effectiveness of environmental control measures to decrease the risk of invasive aspergillosis in acute leukaemia patients during hospital building work","volume":"96","author":"Combariza","year":"2017","journal-title":"J Hosp Infect"},{"key":"2023080202252194900_dkad143-B102","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11046-015-9865-6","article-title":"Invasive aspergillosis in neutropenic patients during hospital renovation: effectiveness of mechanical preventive measures in a prospective cohort of 438 patients","volume":"179","author":"Loschi","year":"2015","journal-title":"Mycopathologia"},{"key":"2023080202252194900_dkad143-B103","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/mmy\/myaa079","article-title":"Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients","volume":"59","author":"Vehreschild","year":"2021","journal-title":"Med Mycol"},{"key":"2023080202252194900_dkad143-B104","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2023080202252194900_dkad143-B105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels","volume":"32","author":"Boogaerts","year":"1989","journal-title":"Mycoses"},{"issue":"Suppl 1","key":"2023080202252194900_dkad143-B106","first-page":"S94","article-title":"Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies","volume":"9","author":"Tricot","year":"1987","journal-title":"Rev Infect Dis"},{"key":"2023080202252194900_dkad143-B107","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2019.06.009","article-title":"National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: evidence of sub-optimal practice","volume":"79","author":"Schelenz","year":"2019","journal-title":"J Infect"},{"key":"2023080202252194900_dkad143-B108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2023080202252194900_dkad143-B109","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111961","article-title":"The overview on the pharmacokinetic and pharmacodynamic interactions of triazoles","volume":"13","author":"Czyrski","year":"2021","journal-title":"Pharmaceutics"},{"key":"2023080202252194900_dkad143-B110","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2023080202252194900_dkad143-B111","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B112","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B113","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B114","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1093\/jac\/dkx228","article-title":"Risk factors for subtherapeutic levels of posaconazole tablet","volume":"72","author":"Tang","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/17425255.2020.1764939","article-title":"Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation","volume":"16","author":"Van Daele","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2023080202252194900_dkad143-B116","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2023080202252194900_dkad143-B117","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2023080202252194900_dkad143-B118","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2023080202252194900_dkad143-B119","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","article-title":"Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2023080202252194900_dkad143-B120","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/myc.12948","article-title":"Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations","volume":"62","author":"M\u00e4rtson","year":"2019","journal-title":"Mycoses"},{"key":"2023080202252194900_dkad143-B121","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/FTD.0000000000000469","article-title":"Early therapeutic drug monitoring of posaconazole oral suspension in patients with hematologic malignancies","volume":"40","author":"Suh","year":"2018","journal-title":"Ther Drug Monit"},{"key":"2023080202252194900_dkad143-B122","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00484-19","article-title":"Treatment by posaconazole tablets, compared to posaconazole suspension, does not reduce variability of posaconazole trough concentrations","volume":"63","author":"Gautier-Veyret","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B123","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.05937-11","article-title":"Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection","volume":"56","author":"Cornely","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1078155216673228","article-title":"Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance","volume":"24","author":"Maleki","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2023080202252194900_dkad143-B125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/AAC.00663-08","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects","volume":"53","author":"Conte","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023080202252194900_dkad143-B126","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/jac\/dkx029","article-title":"Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations","volume":"72","author":"Stott","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023080202252194900_dkad143-B127","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/1120009X.2019.1646974","article-title":"Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study","volume":"31","author":"Wei","year":"2019","journal-title":"J Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/1813\/50967356\/dkad143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/8\/1813\/50967356\/dkad143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T01:30:12Z","timestamp":1729474212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/8\/1813\/7197251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":127,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,6,13]]},"published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad143","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,6,13]]}}}